US EditionAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to ...
- On June 5, 2025, Dr. Reddy's Laboratories and Alvotech announced a joint partnership to co-develop, manufacture, and commercialize a biosimilar candidate of Keytruda for markets worldwide.
- The agreement results from both companies' focus on oncology and builds on their combined capabilities in biosimilars to address the critical immuno-oncology drug pembrolizumab.
- They will collaborate on the development, production, and marketing of the candidate, sharing both costs and duties, with the goal of speeding up progress and broadening their international presence.
- Worldwide sales of Keytruda reached $29.5 billion in 2024, and Dr. Reddy's shares rose by 2.64% to a trading price of ₹1,285 on the NSE following the announcement.
- This collaboration is expected to enhance oncology capabilities for both companies, increase patient access to affordable biologics, and potentially face uncertainties in development and regulatory approvals.
15 Articles
15 Articles
Hastings Tribune
Enid News & EagleAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to ...
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124
Alvotech, Dr Reddy’s partner to develop Keytruda Biosimilar
Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture and commercialise a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Dr Reddy’s, Alvotech partner to develop and commercialize biosimilar of cancer drug Keytruda
Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.
Coverage Details
Bias Distribution
- 43% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
